Clinical Trials During the COVID-19 Pandemic and Beyond: New FDA, NIH Guidance and other Federal Agency Actions to Enable Research

This CLE course will guide healthcare counsel on advising clients conducting clinical trials and other research activities during the COVID-19 pandemic.

The panel will examine recent federal agency guidance on both the conduct and reporting of clinical trials and on flexibilities in federal grant and contract requirements to facilitate research operations in the wake of COVID-19. The panel will also address changes and funding opportunities created by federal legislation passed in response to the COVID-19 pandemic.

The panel will offer guidance and best practices for both ongoing and upcoming trials during the COVID-19 pandemic. Because the panel is composed of attorneys who represent both industry sponsors of research and universities and academic medical centers that serve as clinical research sites, the panel members will offer insights into the relevant guidance and legislation for both types of entities.

Listen as our panel of experienced attorneys provides guidance to healthcare counsel on advising clients conducting clinical trials and other research activities during the COVID-19 pandemic. The panel will discuss the new FDA and NIH guidance as well as other federal agency actions being taken to enable research during the pandemic.